drugset / Trial / NCT05251636

Adjunct Episcleral Brachytherapy for PCV

NCT05251636

Phase 3 Not yet recruiting 159 enrolled Salutaris Medical Devices, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is investigating the use of episcleral brachytherapy (ESB) adjunct to aflibercept compared to aflibercept monotherapy for the treatment of polyploid choroidal vasculopathy (PCV) in patients experiencing an inadequate response to anti-VEGF monotherapy.

Timeline

Start
2025-03
Primary completion
2026-09
Completion
2028-09

Drugs

EvaluationDrugModalityDoseRoute
Background Aflibercept Protein / enzyme biologic Intravitreal